Restructure

Endo rebrands to move beyond roots in pain drugs

Matthew Arnold March 02, 2012

Endo is restructuring, bringing its four operating units under the same corporate roof and rebranding to reflect its diversification out of its origins in pain and urology drugs.

Sanofi braces for patent cliff impact

Matthew Arnold February 09, 2012

Sanofi is girding itself for an ugly year, forecasting a 12%-15% drop in business earnings per share for 2012 as the company absorbs the loss of patent exclusivity on a stable of drugs that brought in more than €4 billion last year.

Abbott to split off branded pharma unit, pursue specialty drug focus

Marc Iskowitz October 19, 2011

Abbott said today it will separate into two publicly traded companies, one its $18-billion pharma unit and the other its $22-billion diversified medical products business.

Digitas Health, Razorfish Health to share new leadership, global team, in efficiency-driven reorg

James Chase June 23, 2011

Digitas Health and Razorfish Health are undergoing an organizational restructure in which the two Publicis-owned siblings will share two newly appointed co-presidents, launch a single global leadership team and develop a variety of centers of excellence.

Video Exclusive

Web Exclusives

Five industry experts advise specialty pharma company on digital strategy

April 20, 2012

Specialty pharma company POZEN assembled a crack team of experts to help shape its digital strategy. Not only did POZEN share with us the text from their contributions, but you can watch exclusive video clips of their valuable perspectives right here.